The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study
第一作者机构：[7]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
推荐引用方式(GB/T 7714)：
Niu Shuhuai.The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA：
Niu, Shuhuai.(2023).The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA：
Niu, Shuhuai."The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)
医学